nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.12.2011 | Original Paper

Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer

verfasst von: Ryo Morita, Kazuhiro Sato, Mariko Nakano, Hajime Miura, Hidesato Odaka, Kiyoshi Nobori, Toshimitsu Kosaka, Masaaki Sano, Hiroyuki Watanabe, Takanobu Shioya, Hiroshi Ito

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Bone marrow-derived endothelial progenitor cells (EPCs) play an important role in angiogenesis and tumor growth. However, the clinical relevance of EPCs in non-small-cell lung cancer (NSCLC) remains unclear. Recently, some reports suggested that EPCs correlate with clinical behavior of cancer patients. We assessed the hypothesis that EPCs correlate with efficient of therapy, prognosis, and clinicopathological factors, and EPCs may offer a possible biomarker for treatment outcome in NSCLC.

Methods

EPCs labeled with CD34, CD133, and vascular endothelial growth factor receptor-2 (VEGFR-2) antibodies were counted by flow cytometry in the peripheral blood of 31 NSCLC patients. We categorized two groups of NSCLC patients according to circulating EPC numbers. We examined age, pathological stage, histological type, Fluoro-d-glucose Positron emission tomography (FDG-PET), response to therapy, progression-free survival, and tumor size of NSCLC patients and investigated whether these factors correlate with EPC counts.

Results

Circulating EPC numbers before antitumor therapy were increased in NSCLC patients compared with healthy controls (P < 0.05). In NSCLC patients, therapy was significantly effective in low circulating EPC group compared with that of high (P < 0.05). Furthermore, the low EPC group showed significantly longer progression-free survival times than that of high (P < 0.05). However, no significant associations with age, gender, histological type, pathological stage, or FDG-PET were detected.

Conclusion

Peripheral blood levels of bone marrow-derived EPCs are significantly increased in patients with NSCLC and correlate with response to chemotherapy. EPCs may offer a possible biomarker for efficient of treatment and prognosis.

Angelo L, Kurzrock R (2007a) Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13:2825–2830PubMedCrossRef

Angelo LS, Kurzrock R (2007b) Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13:2825–2830PubMedCrossRef

Asahara T, Murohara T, Sullivan A, Silver M, Zee R, Li T et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967PubMedCrossRef

Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M et al (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221–228PubMed

Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A, Basolo F et al (2005) Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations. Lung Cancer 50:309–317PubMedCrossRef

Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF et al (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86–91PubMedCrossRef

Bukowski RM (2006) Randomized trial of bevacizumab in advanced renal cell carcinoma. Curr Oncol Rep 10:99–100CrossRef

Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S et al (2006) Identification and clinical significance of circulating endothelial progenitor cells in human non small cell lung cancer. Cancer Res 66:7341–7347PubMedCrossRef

Dome B, Hendrix MJC, Paku S et al (2007) Alternative vascularization mechanisms in cancer. Am J Pathol 170:1–15PubMedCrossRef

Ferrara N (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280:1358–1366

Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMedCrossRef

Folkman J, Watson K, Ingber D, Hanahan D et al (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58–61PubMedCrossRef

George M, Tutton G, Janssen F, Arnaout A, Abulafi AM, Eccles SA et al (2001) VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 3:420–427PubMedCrossRef

Gridelli C, Rossi A, Maione P (2003) Treatment of non small cell lung cancer state of the art and development of new biologic agent. Oncogene 22:6629–6638PubMedCrossRef

Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 3:3243–3256CrossRef

Herbst RS, O’Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L et al (2007) Phase II study of efficacy and safety of bevacizumab in Combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small cell lung cancer. J Clin Oncol 25:4743–4750PubMedCrossRef

Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G, Woll E, Kaher CM (2004) CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non small cell lung cancer. J Clin Pathol 57:965–969PubMedCrossRef

Hristov M, Erl W, Weber PC (2003) Endothelial progenitor cells: isolation and characterization. Trends Cardiovasc Med 13:201–206PubMedCrossRef

Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N et al (2006) Prospective phase II study of gefitinib for chemotherapy naïve patients with advanced non small cell lung cancer with epidermal growth factor receptor gene mutation. J Clin Oncol 24:3340–3346PubMedCrossRef

Khan S, Solomon MA, McCoy JP (2005) Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 64:1–8PubMed

Kim E, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL et al (2008) Gefitinib versus docetaxel in previously treated non small cell lung cancer (INTEREST): a randomized phase III trial. Lancet 372:1809–1818PubMedCrossRef

Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Chadburn A et al (2001) Impaired recruitment of bone marrow derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201PubMedCrossRef

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non small cell lung cancer with mutated EGFR. N Engl J Med 365:2380–2388CrossRef

Mancuso P, Burlini A, Pruneri G, Goldhisch A, Martinelli G, Bertolini F et al (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658–3661PubMedCrossRef

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676PubMedCrossRef

Namdarian B, Tan KV, Fankhauser MJ, Nguyen TT, Corcoran NM, Costello AJ et al (2010) Circulating endothelial cells and progenitors: potential biomarkers of renal cell carcinoma. BJU Int 106:1081–1087PubMedCrossRef

Nowak K, Rafat N, Belle S, Weiss C, Hanusch C, Hohenberger P et al (2010) Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease. Eur J Cardiothorac Surg 37:758–763PubMedCrossRef

Pastorino U, Andreola S, Taglibue E, Pezzella F, Incarbone M, Sozzi G et al (1997) Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15:2858–2865PubMed

Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826–835PubMedCrossRef

Roselli M, Mineo TC, Basili S, Mariotti S, Martini F, Bellotti A et al (2003) Vascular endothelial growth factor (VEGF-A) plasma levels in non small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost 89:177–184PubMed

Sandler A (2007) Bevacizumab in non small cell lung cancer. Clin Cancer Res 13:4613–4616CrossRef

Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM et al (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964–3968PubMed

Titel: Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer
verfasst von: Ryo Morita
Kazuhiro Sato
Mariko Nakano
Hajime Miura
Hidesato Odaka
Kiyoshi Nobori
Toshimitsu Kosaka
Masaaki Sano
Hiroyuki Watanabe
Takanobu Shioya
Hiroshi Ito
Publikationsdatum: 01.12.2011
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-1043-8

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2011

Identification of GLIPR1 tumor suppressor as methylation-silenced gene in acute myeloid leukemia by microarray analysis

Solute carrier protein family may involve in radiation-induced radioresistance of non-small cell lung cancer

Molecular analysis of oncogenicity of the transcription factor, BRN3A, in cervical cancer cells

Interventional therapies of unresectable liver metastases

Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis

A clinicopathological model to predict bone metastasis in hepatocellular carcinoma

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie